Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Scientific (CORZ) Accumulated Expenses (2020 - 2025)

Core Scientific's Accumulated Expenses history spans 6 years, with the latest figure at $180.6 million for Q2 2025.

  • For Q2 2025, Accumulated Expenses rose 524.0% year-over-year to $180.6 million; the TTM value through Jun 2025 reached $180.6 million, up 524.0%, while the annual FY2024 figure was $64.7 million, 64.0% down from the prior year.
  • Accumulated Expenses for Q2 2025 was $180.6 million at Core Scientific, up from $95.5 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $180.6 million in Q2 2025 and bottomed at $692220.0 in Q1 2021.
  • The 5-year median for Accumulated Expenses is $64.7 million (2024), against an average of $67.2 million.
  • The largest annual shift saw Accumulated Expenses surged 16965400.0% in 2021 before it tumbled 73.55% in 2022.
  • A 5-year view of Accumulated Expenses shows it stood at $67.9 million in 2021, then crashed by 73.55% to $18.0 million in 2022, then skyrocketed by 900.65% to $179.6 million in 2023, then tumbled by 64.0% to $64.7 million in 2024, then skyrocketed by 179.33% to $180.6 million in 2025.
  • Per Business Quant, the three most recent readings for CORZ's Accumulated Expenses are $180.6 million (Q2 2025), $95.5 million (Q1 2025), and $64.7 million (Q4 2024).